ClinicalTrials.gg
Active, not recruitingNCT02979522Updated Nov 10, 2026Results posted

A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

A Phase 1/2 interventional study of Brentuximab vedotin and Doxorubicin in Hodgkin Disease, sponsored by Takeda. Active, not recruiting at 14 sites in 4 countries. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Takeda · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
59
Allocation
Non-randomized
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies testing Brentuximab Vedotin in Hodgkin Disease — 14 open to participants now, 28 under way, 8 of them phase 3. Brentuximab Vedotin · Hodgkin Disease.

Enrollment
35th of 80
59 · median 52
Started
2017
with 4 others
Phase 1/2
12 of 80
none open now
Primary completion
2020-05
later than 1 of 27 live
Registered
50th of 80
by date
Lead sponsor
4 of 80
Takeda

Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, this one is the 35th largest by enrollment, is one of 5 that started in 2017, is one of 12 in phase 1/2, reaches primary completion later than 1 of the 27 other live ones, and was the 50th registered.

Hodgkin Disease

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

14 of the 80 studies testing Brentuximab Vedotin in Hodgkin Disease are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About Brentuximab Vedotin

Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies testing Brentuximab Vedotin in Hodgkin Disease, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability, and anti-tumor activity, as well as confirm the recommended dose of brentuximab vedotin (ADCETRIS) in combination with a multiagent chemotherapy regimen, doxorubicin (Adriamycin), vinblastine, and dacarbazine, in pediatric participants with advanced stage newly diagnosed classical CD30+ Hodgkin Lymphoma (HL).

Read the detailed description

The drug being tested in this study is called brentuximab vedotin. Brentuximab vedotin is being tested to treat pediatric participants who have advanced stage, newly diagnosed, classical CD30+ HL. This study will assess the safety, tolerability, and anti-tumor activity, as well as recommended dose of brentuximab vedotin in combination with a multiagent chemotherapy regimen that is based on a current standard of care (SOC) first-line treatment regimen for newly diagnosed HL.

The study will enroll approximately 55 evaluable participants. The study will be conducted in 2 phases, Phase 1 and Phase 2. Phase 1 study will enroll at least 6 participants to determine the recommended dose. Once the recommended dose is identified additional participants will be enrolled into phase 2 so that the total number of evaluable participants will be at least 55, including participants treated at recommended dose in Phase 1. Participants will be enrolled to the following initial dose cohort with an option to explore a reduced dose cohort at 36 mg/m\^2 if needed:

  • Brentuximab vedotin 48 mg/m\^2 in combination with doxorubicin, vinblastine, and dacarbazine.

This multi-center trial will be conducted in the United States, Italy, Brazil and Japan. The overall time to participate in this study is approximately 55 months, including the follow-up period. Participants will be followed for a maximum of 30 days following the last dose of protocol therapy for a follow-up assessment and will be followed for survival and disease status every 12 weeks for 12 months, and then every 24 weeks until death or study closure or for up to 2 years from the date of the last participant enrolled.

03

Conditions studied

  • Hodgkin Disease

Browse trials for

Keywords

  • Drug therapy, pediatric Hodgkin disease, frontline Hodgkin disease, advanced stage Hodgkin disease, pediatric lymphoma
04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Each participant must meet all the following inclusion criteria to be enrolled in the study:

  1. confirmed CD30+ classical HL.
  2. Advanced stage, newly diagnosed HL (Stage III and Stage IV disease).
  3. Treatment-naive HL.
  4. Have performance scores of greater than or equal to (>=) 50 for Lansky Play-performance or Performance Status.
  5. Have bidimensional as documented by radiographic technique per International Working Group (IWG) criteria.
  6. Have adequate blood counts, renal and liver function as defined in the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Nodular lymphocyte predominant HL.
  2. Known active cerebral/meningeal disease, including signs or symptoms of progressive multifocal leukoencephalopathy (PML) or any history of PML.
  3. Any sensory or motor peripheral neuropathy.
  4. Symptomatic neurologic disease compromising normal activities of daily living or requiring medications.
  5. Any active systemic viral, bacterial, or fungal infection requiring systemic antibiotics within 2 weeks before the first study protocol therapy.
  6. Known to recombinant proteins, murine proteins, or to any contained in the drug formulation of brentuximab vedotin or any component of AVD.
  7. Known positive.
  8. Known surface antigen positive or known or suspected active infection, as determined by hepatitis B DNA or hepatitis C RNA, respectively, in blood.
  9. Diagnosed or treated for another within 3 years before the first dose or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
  10. Use of any strong or listed moderate cytochrome P450 (CYP) 3A4 inhibitors less than (\<) 2 weeks before the first dose of protocol therapy (please refer to the Study Manual for an example list of prohibited inhibitors).
  11. Any of the following cardiovascular conditions or values within 6 months before the first dose of protocol therapy:

    • Shortening fraction of \<27 percent (%) by echocardiogram or, if echocardiogram not feasible, of \<50% by radionuclide angiogram (RNA or MUGA [multiple-gated acquisition scan]).
    • Class III or IV heart failure.
    • Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure, angina, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Phase 1: Brentuximab Vedotin 48 mg/m^2 + AVD

    Brentuximab vedotin 48 mg/m\^2 (A), intravenous infusion, once on Days 1 and 15 of each 28-day cycle approximately 1 hour after administration of doxorubicin 25 mg/m\^2, vinblastine 6 mg/m\^2, and dacarbazine 375 mg/m\^2 (AVD), intravenous infusion, once on Days 1 and 15 of each 28-day cycle for up to 6 cycles.

    Drug: Brentuximab vedotin · Drug: Doxorubicin · Drug: Vinblastine · Drug: Dacarbazine

  • Experimental
    Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD

    Brentuximab vedotin 48 mg/m\^2 (A), intravenous infusion, once on Days 1 and 15 of each 28-day cycle approximately 1 hour after administration of doxorubicin 25 mg/m\^2, vinblastine 6 mg/m\^2, and dacarbazine 375 mg/m\^2 (AVD), intravenous infusion, once on Days 1 and 15 of each 28-day cycle for up to 6 cycles.

    Drug: Brentuximab vedotin · Drug: Doxorubicin · Drug: Vinblastine · Drug: Dacarbazine

Interventions

06

What researchers measure

Primary outcomes

  1. Phase 1: Recommended Dose of Brentuximab Vedotin in Combination With Doxorubicin, Vinblastine, and Dacarbazine in a Pediatric Population

    The recommended dose was determined after considering all safety data in phase 1 and assessing for dose limiting toxicities (DLTs) which are defined as the dose range at which less than or equal to (\<=) 1 of 6 evaluable participants experience DLT within the defined observation period (Cycle 1 + 28 days). This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.

    Time frame: From the first dose (Cycle 1) up to Day 56 (Cycle length=28 days)

  2. Phase 1: Percentage of Participants Who Experienced Adverse Events (AEs) From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy

    AE means any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to the medicinal product. This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.

    Time frame: From first dose in Cycle 1 Day 1 until 30 days after the last dose of study drug in Cycle 6 Day 15 (up to Cycle 7 Day 15) (Cycle length=28 days)

  3. Phase 1: Percentage of Participants Who Experienced Serious Adverse Events (SAEs) From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy

    AE means any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to the medicinal product. SAE is defined as any untoward medical occurrence that at any dose results in death, Is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, Is a congenital anomaly/birth defect, Is a medically important event.

    Time frame: From first dose in Cycle 1 Day 1 until 30 days after the last dose of study drug in Cycle 6 Day 15 (up to Cycle 7 Day 15) (Cycle length=28 days)

  4. Phase 2: Percentage of Participants Who Achieved a Complete Remission (CR) Per Independent Review Facility (IRF) Assessment Per International Working Group (IWG) Criteria at End of Treatment (EOT) Visit

    CR was defined as the disappearance of all evidence of disease as assessed by IRF as per IWG Criteria. The confidence interval was based on exact binomial distribution (Clopper-Pearson method). This outcome measure was planned to be assessed for all participants treated at the recommended dose in Phase 2. As prespecified in the statistical analysis plan (SAP) , data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: At end of treatment (EOT) visit 30 days after the last dose of study drug (at Month 7)

  5. Phase 2: Percentage of Participants Whose Disease Was Positron Emission Tomography (PET) Negative After 2 Cycles of Protocol Therapy Per IRF Assessment

    The Deauville score according to IRF assessment of response was used to evaluate the results of PET scans. PET negative after Cycle 2 was defined as an IRF Deauville score of (1 or 2 or 3). This outcome measure was planned to be assessed for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: From first dose of study drug up to Cycle 2 Day 25 (Each Cycle length=28 days)

  6. Phase 2: Percentage of Participants Who Achieved a Partial Remission (PR) Per IRF Assessment Per IWG Criteria at EOT Visit

    PR was defined as regression of measurable disease and no new sites as assessed by IRF as per IWG criteria. Percentage of participants in the response-evaluable population who achieved a partial response based on the IRF assessment at the EOT visit based on the IWG criteria are reported. The confidence interval was based on exact binomial distribution (Clopper-Pearson method). This outcome measure was planned to be assessed for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: At EOT visit 30 days after the last dose of study drug (at Month 7)

  7. Phase 2: Percentage of Participants Who Achieved an Overall Response Rate (ORR) Per IRF Assessment Per IWG Criteria at EOT Visit

    Overall response rate was defined as the percentage of participants with CR or PR as assessed by IRF using IWG criteria. CR was defined as the disappearance of all evidence of disease and PR was defined as regression of measurable disease and no new diseases. The confidence interval was based on exact binomial distribution (Clopper-Pearson method). This outcome measure was planned to be assessed for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: At EOT visit 30 days after the last dose of study drug (at Month 7)

  8. Phase 2: Percentage of Participants Who Were Able to Complete 6 Cycles of Protocol Therapy at the Recommended Dose

    This outcome measure was planned to be assessed for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: From first dose of study drug up to Cycle 6 (Each Cycle length=28 days)

Secondary outcomes

  1. Phase 1: Mean Maximum Observed Serum Concentration (Cmax) of Brentuximab Vedotin Total Conjugated and Therapeutic Antibody (TAb)

    This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.

    Time frame: Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)

  2. Phase 1: Mean Maximum Observed Plasma Concentration (Cmax) of Monomethyl Auristatin E (MMAE)

    This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.

    Time frame: Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)

  3. Phase 1: Mean Area Under the Serum Concentration-Time Curve From Day 0 to Day 15 (AUC0-15) of Brentuximab Vedotin and TAb

    This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.

    Time frame: Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)

  4. Phase 1: Mean Area Under the Plasma Concentration-Time Curve From Day 0 to Day 15 (AUC0-15) of MMAE

    This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.

    Time frame: Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)

  5. Phase 1: Median Time to Reach Cmax (Tmax) of Brentuximab Vedotin and TAb in Serum

    This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.

    Time frame: Cycle 1-6: Days 1 and 15 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)

  6. Phase 1: Median Time to Reach Cmax (Tmax) of MMAE in Plasma

    This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.

    Time frame: Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)

  7. Phase 1: Percentage of Participants Who Achieved a CR Per IRF Assessment Per IWG Criteria at EOT Visit

    CR was defined as the disappearance of all evidence of disease as assessed by IRF as per IWG Criteria. The confidence interval was based on exact binomial distribution (Clopper-Pearson method). This outcome measure was planned to be assessed only for participants treated in Phase 1 arm.

    Time frame: At EOT visit 30 days after the last dose of study drug (at Month 7)

  8. Phase 1: Percentage of Participants Who Achieved a PR Per IRF Assessment Per IWG Criteria at EOT Visit

    PR was defined as regression of measurable disease and no new diseases as per IWG Criteria based on IRF. The confidence interval was based on exact binomial distribution (Clopper-Pearson method). This outcome measure was planned to be assessed only for participants treated in Phase 1 arm.

    Time frame: At EOT visit 30 days after the last dose of study drug (at Month 7)

  9. Phase 1: Percentage of Participants Who Achieved an ORR Per IRF Assessment Per IWG Criteria at EOT Visit

    Overall response rate was defined as the percentage of participants with CR or PR as assessed by an IRF using IWG Revised Response Criteria. CR was defined as the disappearance of all evidence of disease and PR was defined as regression of measurable disease and no new sites. The confidence interval was based on exact binomial distribution (Clopper-Pearson method). This outcome measure was planned to be assessed only for participants treated in Phase 1 arm.

    Time frame: At EOT visit 30 days after the last dose of study drug (at Month 7)

  10. Phase 1: Percentage of Participants Whose Disease Was PET Negative After 2 Cycles of Protocol Therapy Per IRF Assessment

    The Deauville score according to IRF assessment of response was used to evaluate the results of PET scans. PET negative after Cycle 2 was defined as an IRF Deauville score of (1 or 2 or 3). This outcome measure was planned to be assessed only for participants treated in Phase 1 arm.

    Time frame: From first dose of study drug up to Cycle 2 (Each Cycle length=28 days)

  11. Phase 1: Percentage of Participants Whose Disease Was PET Positive After 6 Cycles of Protocol Therapy Per IRF Assessment

    The Deauville score according to IRF assessment of response was used to evaluate the results of PET scans. PET positive after Cycle 6 defined as an IRF Deauville score of (4 or 5). This outcome measure was planned to be assessed only for participants treated in Phase 1 arm.

    Time frame: From first dose of study drug up to Cycle 6 (Each Cycle length=28 days)

  12. Phase 1: Percentage of Participants Who Were Antitherapeutic Antibody (ATA) Positive, Persistently Positive or Transiently Positive, and Neutralizing Antitherapeutic Antibody (nATA) Positive

    ATA positive was defined as participants who have a positive ATA in any postbaseline sample. Transiently ATA positive was defined as participants who have positive ATA in 1 or 2 postbaseline samples. Persistently ATA positive was defined as participants who have positive ATA in more than 2 postbaseline timepoints. Transiently ATA positive was defined as participants who have positive ATA in 1 or 2 postbaseline samples. nATA positive was defined as participants who have at least one positive nATA in any postbaseline ATA positive sample. Here, percentage of participants who were transiently or persistently ATA positive are considered as ATA positive. This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.

    Time frame: Up to 7 months

  13. Phase 2: Progression-free Survival (PFS)

    PFS per IRF:time from first dose until disease progression per IRF/death due to any cause,whichever occurred first.Participants with no objective progressive disease (PD),did not die,were still on study follow-up at time of analysis were removed from study prior to documentation of PD,PFS was censored on date of last adequate disease assessment before initiation of any non-protocol,alternative therapy.Participants who were on antitumor treatment,other than SCT/radiotherapy,censoring was at last adequate disease assessment before initiation of such alternative treatment.If participant experienced disease progression per IRF/died after initiation of antitumor treatment,other than SCT/radiotherapy,such participant was censored and not considered having PFS.Outcome measure was planned to be assessed for all participant treated at recommended dose in Phase 2.As per SAP,Phase 2 data was summarized and reported in two arms:Phase 2 and Phase 1 + Phase 2.

    Time frame: Up to 24 months

  14. Phase 2: Event-free Survival (EFS)

    EFS:Time from first dose until any treatment failure:PD per IRF including progression events during follow-up period,failing to complete 6 cycles of treatment due to any reason or death due to any cause,whichever occurred first.EFS per IRF were censored on last adequate disease assessment date per IRF if none of above events occur during study.Participants with antitumor treatment,other than SCT/radiotherapy as part of frontline treatment were censored at last adequate disease assessment before initiation of such alternative treatment.If a participant experienced disease progression per IRF/died after initiation of antitumor treatment,other than SCT/radiotherapy,such participant was censored,and not be considered having EFS.This outcome measure was planned to be assessed for all patients treated at recommended dose in Phase 2.As prespecified in SAP,data for Phase 2 was summarized and reported in two arms:Phase 2 and Phase 1 + Phase 2.

    Time frame: Up to 24 months

  15. Phase 2: Overall Survival (OS)

    Overall survival was defined as time from first dose until death. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive, including study closure. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: Up to 24 months

  16. Phase 2: Duration of Response (DOR)

    DOR per IRF in participants with a response (CR or PR per IRF) was defined as the time from start of the first objective tumor response (CR or PR per IRF) to the first subsequent PD or death due to any cause, whichever occurred first. For patients who did not have an objective PD, did not die and are either still on a study follow-up at the time of the analysis, or were removed from the study prior to documentation of PD, DOR has been censored on the date of last adequate disease assessment. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: Up to 24 months

  17. Phase 2: Percentage of Participants Receiving Irradiation for HL Following Study Treatment

    This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: Up to 24 months

  18. Phase 2: Percentage of Participants Who Experienced AEs From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy

    This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: From first dose in Cycle 1 Day 1 until 30 days after the last dose of study drug in Cycle 6 Day 15 (up to Cycle 7 Day 15) (Cycle length=28 days)

  19. Phase 2: Percentage of Participants Who Experienced SAEs From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy

    This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: From first dose in Cycle 1 Day 1 until 30 days after the last dose of study drug in Cycle 6 Day 15 (up to Cycle 7 Day 15) (Cycle length=28 days)

  20. Phase 2: Percentage of Participants Who Were ATA Positive, Persistently Positive, or Transiently Positive, and nATA Positive

    ATA positive was defined as participants who have a positive ATA in any postbaseline sample. Transiently ATA positive was defined as participants who have positive ATA in 1 or 2 postbaseline samples. Persistently ATA positive was defined as participants who have positive ATA in more than 2 postbaseline timepoints. Transiently ATA positive was defined as participants who have positive ATA in 1 or 2 postbaseline samples. nATA positive was defined as participants who have at least one positive nATA in any postbaseline ATA positive sample. Here, percentage of participants who were transiently or persistently ATA positive are considered as ATA positive. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: From first dose until 30 days after the last dose of study drug (up to 7 months)

  21. Phase 2: Mean Serum Cmax of Brentuximab Vedotin and TAb

    This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)

  22. Phase 2: Mean Plasma Cmax of MMAE

    This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)

  23. Phase 2: Mean Serum AUC0-15d of Brentuximab Vedotin and TAb

    This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)

  24. Phase 2: Mean Plasma AUC0-15 of MMAE

    This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)

  25. Phase 2: Median Tmax of Brentuximab Vedotin and TAb in Serum

    This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)

  26. Phase 2: Median Tmax of MMAE in Plasma

    This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)

  27. Phase 2: Percentage of Participants Who Experienced Peripheral Neuropathy, Regardless of Seriousness, From the First Dose of Protocol Therapy

    Peripheral Neuropathy (PN) was defined by the peripheral neuropathy standardized MedDRA query (SMQ) broad search. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: Up to 24 months

  28. Phase 2: Time to Onset and Resolution for All Peripheral Neuropathy Events

    Time to onset of first event was defined as time from first dose of study drug to onset of first treatment-emergent PN event. Time to resolution was calculated as the time from onset date to the date of resolution PN (SMQ) event. Participants with multiple resolved events were counted once at the longest time to resolution. Resolution was defined as an event outcome of resolved or resolved with sequelae. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: Up to 24 months

  29. Phase 2: Immune Reconstitution-Change From Baseline Immunoglobulin G Levels at End of Treatment (EOT)

    This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: Baseline and End of Treatment (Month 7)

  30. Phase 1: Percentage of Participants With Low and High ATA Titer Values

    High ATA titer was defined as participants who have at least one postbaseline ATA titer less than (\>) 25. Low ATA titer was defined as participants whose postbaseline ATA titer are all less than or equal to (\<=) 25. This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.

    Time frame: Up to 6 months

  31. Phase 2: Percentage of Participants With Low and High ATA Titer Values

    High ATA titer was defined as participants who have at least one postbaseline ATA titer \>25. Low ATA titer was defined as participants whose postbaseline ATA titer are all \<=25. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: Up to 6 months

  32. Phase 1: Mean Cmax of Brentuximab Vedotin in ATA Positive and ATA Negative Participants

    This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.

    Time frame: Cycle 1 and 3: Days 1 and 15 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)

  33. Phase 1: Mean AUC 0-15d of Brentuximab Vedotin in ATA Positive and ATA Negative Participants

    This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.

    Time frame: Cycle 1 and 3: Days 1 and 15 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)

  34. Phase 1: Percentage of Participants Achieving CR Per IRF Assessment Per IWG Criteria in ATA Positive and ATA Negative Participants

    CR was defined as the disappearance of all evidence of disease as assessed by IRF as per IWG Criteria. The data is reported per ATA status as categories. This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.

    Time frame: Up to 24 months

  35. Phase 1: Number of ATA Positive and ATA Negative Participants With AEs and SAEs

    This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.

    Time frame: Up to 24 months

  36. Phase 2: Mean Cmax of Brentuximab Vedotin in ATA Positive and ATA Negative Participants

    This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: Cycle 1-3: Days 1 and 15 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)

  37. Phase 2: Mean AUC 0-15 of Brentuximab Vedotin in ATA Positive and ATA Negative Participants

    This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: Cycle 1-3: Days 1 and 15 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)

  38. Phase 2: Percentage of Participants Achieving CR Per IRF Assessment Per IWG Criteria in ATA Positive and ATA Negative Participants

    CR is defined as the disappearance of all evidence of disease as assessed by IRF as per IWG Criteria. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: Up to 24 months

  39. Phase 2: Number of ATA Positive and ATA Negative Participants With AEs and SAEs

    This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: Up to 24 months

  40. Phase 2: Immune Reconstitution-Change From Baseline in Immunoglobulin M at the End of Treatment (EOT)

    This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: Baseline, EOT [Month 7]

  41. Phase 2: Immune Reconstitution-Change From Baseline in Immunoglobulin A at EOT

    This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: Baseline, EOT [Month 7]

  42. Phase 2: Immune Reconstitution-Change From Baseline in Tetanus at EOT

    This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: Baseline, EOT [Month 7]

  43. Phase 2: Immune Reconstitution-Change From Baseline in Haemophilus Influenzae B Antibody, IgG at EOT

    This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: Baseline, EOT [Month 7]

  44. Phase 2: Immune Reconstitution-Change From Baseline Poliovirus Antibodies Ratio at EOT

    This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: Baseline, EOT [Month 7]

  45. Phase 2: Immune Reconstitution-Change From Baseline Total Immunoglobulin at EOT

    This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: Baseline, EOT [Month 7]

  46. Phase 2: Immune Reconstitution-Change From Baseline in Peripheral Blood CD34+A at EOT

    This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: Baseline, EOT [Month 7]

  47. Phase 2: Immune Reconstitution-Change From Baseline in Total Lymphocyte Count at EOT

    This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: Baseline, EOT [Month 7]

  48. Phase 2: Immune Reconstitution-Change From Baseline in the Percentage of CD4+ (CD4+CD45RA-CD197- and CD4+CD45RA+CD197+) Subset of Cells at EOT

    This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: Baseline, EOT [Month 7]

  49. Phase 2: Immune Reconstitution-Change From Baseline in the Percentage of CD8+ (CD8+CD45RA-CD197- and CD8+CD45RA-CD197+) Subset of Cells at EOT

    This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

    Time frame: Baseline, EOT [Month 7]

07

Results

Posted Jun 1, 2021

Participant flow

Participants with advanced stage newly diagnosed, classical CD30+ Hodgkin Lymphoma (HL) took part in the study at 14 investigative sites in the United States, Italy, Brazil and Japan from 06 September 2017 to data cut-off date: 24 September 2021. This study is ongoing for Post-Treatment Follow-Up (which includes Progression-Free Survival Follow-Up \[PFSFU\] and Overall Survival Follow-Up \[OSFU\]) and optional Long-Term Safety Follow-up.

Participant flow — Overall Study
MilestonePhase 1: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Started851
Completed00
Not completed851
Withdrew: Post-treatment follow-up (pfsfu and osfu)028
Withdrew: Particpants ongoing in long-term safety follow-up823

Outcome measures

PrimaryPhase 1: Recommended Dose of Brentuximab Vedotin in Combination With Doxorubicin, Vinblastine, and Dacarbazine in a Pediatric Population

The recommended dose was determined after considering all safety data in phase 1 and assessing for dose limiting toxicities (DLTs) which are defined as the dose range at which less than or equal to (\<=) 1 of 6 evaluable participants experience DLT within the defined observation period (Cycle 1 + 28 days). This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.

Time frame:
From the first dose (Cycle 1) up to Day 56 (Cycle length=28 days)
Reported as:
Number · mg/m^2
Phase 1: Recommended Dose of Brentuximab Vedotin in Combination With Doxorubicin, Vinblastine, and Dacarbazine in a Pediatric Population
mg/m^2Phase 1: Brentuximab Vedotin 48 mg/m^2 +AVD
Phase 1: Recommended Dose of Brentuximab Vedotin in Combination With Doxorubicin, Vinblastine, and Dacarbazine in a Pediatric Population48
PrimaryPhase 1: Percentage of Participants Who Experienced Adverse Events (AEs) From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy

AE means any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to the medicinal product. This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.

Time frame:
From first dose in Cycle 1 Day 1 until 30 days after the last dose of study drug in Cycle 6 Day 15 (up to Cycle 7 Day 15) (Cycle length=28 days)
Reported as:
Number · percentage of participants
Phase 1: Percentage of Participants Who Experienced Adverse Events (AEs) From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy
percentage of participantsPhase 1: Brentuximab Vedotin 48 mg/m^2 +AVD
Phase 1: Percentage of Participants Who Experienced Adverse Events (AEs) From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy100
PrimaryPhase 1: Percentage of Participants Who Experienced Serious Adverse Events (SAEs) From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy

AE means any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to the medicinal product. SAE is defined as any untoward medical occurrence that at any dose results in death, Is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, Is a congenital anomaly/birth defect, Is a medically important event.

Time frame:
From first dose in Cycle 1 Day 1 until 30 days after the last dose of study drug in Cycle 6 Day 15 (up to Cycle 7 Day 15) (Cycle length=28 days)
Reported as:
Number · percentage of participants
Phase 1: Percentage of Participants Who Experienced Serious Adverse Events (SAEs) From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy
percentage of participantsPhase 1: Brentuximab Vedotin 48 mg/m^2 +AVD
Phase 1: Percentage of Participants Who Experienced Serious Adverse Events (SAEs) From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy13
PrimaryPhase 2: Percentage of Participants Who Achieved a Complete Remission (CR) Per Independent Review Facility (IRF) Assessment Per International Working Group (IWG) Criteria at End of Treatment (EOT) Visit

CR was defined as the disappearance of all evidence of disease as assessed by IRF as per IWG Criteria. The confidence interval was based on exact binomial distribution (Clopper-Pearson method). This outcome measure was planned to be assessed for all participants treated at the recommended dose in Phase 2. As prespecified in the statistical analysis plan (SAP) , data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
At end of treatment (EOT) visit 30 days after the last dose of study drug (at Month 7)
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants Who Achieved a Complete Remission (CR) Per Independent Review Facility (IRF) Assessment Per International Working Group (IWG) Criteria at End of Treatment (EOT) Visit
percentage of participantsPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Phase 2: Percentage of Participants Who Achieved a Complete Remission (CR) Per Independent Review Facility (IRF) Assessment Per International Working Group (IWG) Criteria at End of Treatment (EOT) Visit75 (60 to 86)76 (63 to 86)
PrimaryPhase 2: Percentage of Participants Whose Disease Was Positron Emission Tomography (PET) Negative After 2 Cycles of Protocol Therapy Per IRF Assessment

The Deauville score according to IRF assessment of response was used to evaluate the results of PET scans. PET negative after Cycle 2 was defined as an IRF Deauville score of (1 or 2 or 3). This outcome measure was planned to be assessed for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
From first dose of study drug up to Cycle 2 Day 25 (Each Cycle length=28 days)
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants Whose Disease Was Positron Emission Tomography (PET) Negative After 2 Cycles of Protocol Therapy Per IRF Assessment
percentage of participantsPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Phase 2: Percentage of Participants Whose Disease Was Positron Emission Tomography (PET) Negative After 2 Cycles of Protocol Therapy Per IRF Assessment9090
PrimaryPhase 2: Percentage of Participants Who Achieved a Partial Remission (PR) Per IRF Assessment Per IWG Criteria at EOT Visit

PR was defined as regression of measurable disease and no new sites as assessed by IRF as per IWG criteria. Percentage of participants in the response-evaluable population who achieved a partial response based on the IRF assessment at the EOT visit based on the IWG criteria are reported. The confidence interval was based on exact binomial distribution (Clopper-Pearson method). This outcome measure was planned to be assessed for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
At EOT visit 30 days after the last dose of study drug (at Month 7)
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants Who Achieved a Partial Remission (PR) Per IRF Assessment Per IWG Criteria at EOT Visit
percentage of participantsPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Phase 2: Percentage of Participants Who Achieved a Partial Remission (PR) Per IRF Assessment Per IWG Criteria at EOT Visit12 (6 to 20)12 (5 to 23)
PrimaryPhase 2: Percentage of Participants Who Achieved an Overall Response Rate (ORR) Per IRF Assessment Per IWG Criteria at EOT Visit

Overall response rate was defined as the percentage of participants with CR or PR as assessed by IRF using IWG criteria. CR was defined as the disappearance of all evidence of disease and PR was defined as regression of measurable disease and no new diseases. The confidence interval was based on exact binomial distribution (Clopper-Pearson method). This outcome measure was planned to be assessed for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
At EOT visit 30 days after the last dose of study drug (at Month 7)
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants Who Achieved an Overall Response Rate (ORR) Per IRF Assessment Per IWG Criteria at EOT Visit
percentage of participantsPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Phase 2: Percentage of Participants Who Achieved an Overall Response Rate (ORR) Per IRF Assessment Per IWG Criteria at EOT Visit86 (74 to 94)88 (77 to 95)
PrimaryPhase 2: Percentage of Participants Who Were Able to Complete 6 Cycles of Protocol Therapy at the Recommended Dose

This outcome measure was planned to be assessed for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
From first dose of study drug up to Cycle 6 (Each Cycle length=28 days)
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants Who Were Able to Complete 6 Cycles of Protocol Therapy at the Recommended Dose
percentage of participantsPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Phase 2: Percentage of Participants Who Were Able to Complete 6 Cycles of Protocol Therapy at the Recommended Dose100100
SecondaryPhase 1: Mean Maximum Observed Serum Concentration (Cmax) of Brentuximab Vedotin Total Conjugated and Therapeutic Antibody (TAb)

This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.

Time frame:
Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Reported as:
Mean · microgram per milliliter(mcg/mL)
Phase 1: Mean Maximum Observed Serum Concentration (Cmax) of Brentuximab Vedotin Total Conjugated and Therapeutic Antibody (TAb)
microgram per milliliter(mcg/mL)Phase 1: Brentuximab Vedotin 48 mg/m^2 +AVD
Conjugate Brentuximab Vedotin at Cycle 1 Day 122.6 ± 1.51
Conjugate Brentuximab Vedotin at Cycle 1 Day 1523.1 ± 3.85
Conjugate Brentuximab Vedotin at Cycle 3 Day 126.7 ± 3.65
Conjugate Brentuximab Vedotin at Cycle 3 Day 1527.3 ± 7.14
TAb at Cycle 1 Day 124.9 ± 3.84
TAb at Cycle 1 Day 1525.5 ± 5.28
TAb at Cycle 3 Day 129.6 ± 4.05
TAb at Cycle 3 Day 1528.1 ± 7.45
SecondaryPhase 1: Mean Maximum Observed Plasma Concentration (Cmax) of Monomethyl Auristatin E (MMAE)

This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.

Time frame:
Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Reported as:
Mean · nanogram per milliliter (ng/ml)
Phase 1: Mean Maximum Observed Plasma Concentration (Cmax) of Monomethyl Auristatin E (MMAE)
nanogram per milliliter (ng/ml)Phase 1: Brentuximab Vedotin 48 mg/m^2 +AVD
Cycle 1 Day 15.51 ± 3.91
Cycle 1 Day 152.08 ± 0.677
Cycle 3 Day 11.38 ± 0.514
Cycle 3 Day 151.19 ± 0.366
SecondaryPhase 1: Mean Area Under the Serum Concentration-Time Curve From Day 0 to Day 15 (AUC0-15) of Brentuximab Vedotin and TAb

This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.

Time frame:
Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Reported as:
Mean · day*microgram per milliliter(day*mcg/mL)
Phase 1: Mean Area Under the Serum Concentration-Time Curve From Day 0 to Day 15 (AUC0-15) of Brentuximab Vedotin and TAb
day*microgram per milliliter(day*mcg/mL)Phase 1: Brentuximab Vedotin 48 mg/m^2 +AVD
AUC0-15d of Brentuximab Vedotin at Cycle 1 Day 142.3 ± 3.10
AUC0-15d of Brentuximab Vedotin at Cycle 1 Day 1548.8 ± 5.83
AUC0-15d of Brentuximab Vedotin at Cycle 3 Day 172.7 ± 27.8
AUC0-15d of Brentuximab Vedotin at Cycle 3 Day 1564.8 ± 13.5
AUC0-15d of TAb at Cycle 1 Day 180.6 ± 13.0
AUC0-15d of TAb at Cycle 1 Day 15103 ± 14.6
AUC0-15d of TAb at Cycle 3 Day 1127 ± 10.2
AUC0-15d of TAb at Cycle 3 Day 15128 ± 34.4
SecondaryPhase 1: Mean Area Under the Plasma Concentration-Time Curve From Day 0 to Day 15 (AUC0-15) of MMAE

This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.

Time frame:
Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Reported as:
Mean · day* nanogram per milliliter (day*ng/mL)
Phase 1: Mean Area Under the Plasma Concentration-Time Curve From Day 0 to Day 15 (AUC0-15) of MMAE
day* nanogram per milliliter (day*ng/mL)Phase 1: Brentuximab Vedotin 48 mg/m^2 +AVD
Cycle 1 Day 129.8 ± 21.2
Cycle 1 Day 1513.1 ± 2.99
Cycle 3 Day 18.88 ± 2.53
Cycle 3 Day 157.17 ± 2.17
SecondaryPhase 1: Median Time to Reach Cmax (Tmax) of Brentuximab Vedotin and TAb in Serum

This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.

Time frame:
Cycle 1-6: Days 1 and 15 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Reported as:
Median · hour
Phase 1: Median Time to Reach Cmax (Tmax) of Brentuximab Vedotin and TAb in Serum
hourPhase 1: Brentuximab Vedotin 48 mg/m^2 +AVD
Tmax of Brentuximab Vedotin at Cycle 1 Day 11.00 (0.570 to 1.05)
Tmax of Brentuximab Vedotin at Cycle 1 Day 150.915 (0.580 to 1.00)
Tmax of Brentuximab Vedotin at Cycle 3 Day 11.00 (0.630 to 1.17)
Tmax of Brentuximab Vedotin at Cycle 3 Day 150.830 (0.580 to 1.00)
Tmax of TAb at Cycle 1 Day 11.00 (0.570 to 1.05)
Tmax of TAb at Cycle 1 Day 150.915 (0.580 to 1.00)
SecondaryPhase 1: Median Time to Reach Cmax (Tmax) of MMAE in Plasma

This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.

Time frame:
Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Reported as:
Median · hour
Phase 1: Median Time to Reach Cmax (Tmax) of MMAE in Plasma
hourPhase 1: Brentuximab Vedotin 48 mg/m^2 +AVD
Cycle 1 Day 144.9 (21.1 to 69.1)
Cycle 1 Day 1543.1 (41.2 to 45.9)
Cycle 3 Day 148.0 (42.3 to 66.9)
Cycle 3 Day 1548.2 (20.8 to 67.0)
SecondaryPhase 1: Percentage of Participants Who Achieved a CR Per IRF Assessment Per IWG Criteria at EOT Visit

CR was defined as the disappearance of all evidence of disease as assessed by IRF as per IWG Criteria. The confidence interval was based on exact binomial distribution (Clopper-Pearson method). This outcome measure was planned to be assessed only for participants treated in Phase 1 arm.

Time frame:
At EOT visit 30 days after the last dose of study drug (at Month 7)
Reported as:
Number · percentage of participants
Phase 1: Percentage of Participants Who Achieved a CR Per IRF Assessment Per IWG Criteria at EOT Visit
percentage of participantsPhase 1: Brentuximab Vedotin 48 mg/m^2 +AVD
Phase 1: Percentage of Participants Who Achieved a CR Per IRF Assessment Per IWG Criteria at EOT Visit88 (47 to 100)
SecondaryPhase 1: Percentage of Participants Who Achieved a PR Per IRF Assessment Per IWG Criteria at EOT Visit

PR was defined as regression of measurable disease and no new diseases as per IWG Criteria based on IRF. The confidence interval was based on exact binomial distribution (Clopper-Pearson method). This outcome measure was planned to be assessed only for participants treated in Phase 1 arm.

Time frame:
At EOT visit 30 days after the last dose of study drug (at Month 7)
Reported as:
Number · percentage of participants
Phase 1: Percentage of Participants Who Achieved a PR Per IRF Assessment Per IWG Criteria at EOT Visit
percentage of participantsPhase 1: Brentuximab Vedotin 48 mg/m^2 +AVD
Phase 1: Percentage of Participants Who Achieved a PR Per IRF Assessment Per IWG Criteria at EOT Visit13 (1 to 53)
SecondaryPhase 1: Percentage of Participants Who Achieved an ORR Per IRF Assessment Per IWG Criteria at EOT Visit

Overall response rate was defined as the percentage of participants with CR or PR as assessed by an IRF using IWG Revised Response Criteria. CR was defined as the disappearance of all evidence of disease and PR was defined as regression of measurable disease and no new sites. The confidence interval was based on exact binomial distribution (Clopper-Pearson method). This outcome measure was planned to be assessed only for participants treated in Phase 1 arm.

Time frame:
At EOT visit 30 days after the last dose of study drug (at Month 7)
Reported as:
Number · percentage of participants
Phase 1: Percentage of Participants Who Achieved an ORR Per IRF Assessment Per IWG Criteria at EOT Visit
percentage of participantsPhase 1: Brentuximab Vedotin 48 mg/m^2 +AVD
Phase 1: Percentage of Participants Who Achieved an ORR Per IRF Assessment Per IWG Criteria at EOT Visit100 (63 to 100)
SecondaryPhase 1: Percentage of Participants Whose Disease Was PET Negative After 2 Cycles of Protocol Therapy Per IRF Assessment

The Deauville score according to IRF assessment of response was used to evaluate the results of PET scans. PET negative after Cycle 2 was defined as an IRF Deauville score of (1 or 2 or 3). This outcome measure was planned to be assessed only for participants treated in Phase 1 arm.

Time frame:
From first dose of study drug up to Cycle 2 (Each Cycle length=28 days)
Reported as:
Number · percentage of participants
Phase 1: Percentage of Participants Whose Disease Was PET Negative After 2 Cycles of Protocol Therapy Per IRF Assessment
percentage of participantsPhase 1: Brentuximab Vedotin 48 mg/m^2 +AVD
Phase 1: Percentage of Participants Whose Disease Was PET Negative After 2 Cycles of Protocol Therapy Per IRF Assessment88 (47 to 100)
SecondaryPhase 1: Percentage of Participants Whose Disease Was PET Positive After 6 Cycles of Protocol Therapy Per IRF Assessment

The Deauville score according to IRF assessment of response was used to evaluate the results of PET scans. PET positive after Cycle 6 defined as an IRF Deauville score of (4 or 5). This outcome measure was planned to be assessed only for participants treated in Phase 1 arm.

Time frame:
From first dose of study drug up to Cycle 6 (Each Cycle length=28 days)
Reported as:
Number · percentage of participants
Phase 1: Percentage of Participants Whose Disease Was PET Positive After 6 Cycles of Protocol Therapy Per IRF Assessment
percentage of participantsPhase 1: Brentuximab Vedotin 48 mg/m^2 +AVD
Phase 1: Percentage of Participants Whose Disease Was PET Positive After 6 Cycles of Protocol Therapy Per IRF Assessment13 (1 to 53)
SecondaryPhase 1: Percentage of Participants Who Were Antitherapeutic Antibody (ATA) Positive, Persistently Positive or Transiently Positive, and Neutralizing Antitherapeutic Antibody (nATA) Positive

ATA positive was defined as participants who have a positive ATA in any postbaseline sample. Transiently ATA positive was defined as participants who have positive ATA in 1 or 2 postbaseline samples. Persistently ATA positive was defined as participants who have positive ATA in more than 2 postbaseline timepoints. Transiently ATA positive was defined as participants who have positive ATA in 1 or 2 postbaseline samples. nATA positive was defined as participants who have at least one positive nATA in any postbaseline ATA positive sample. Here, percentage of participants who were transiently or persistently ATA positive are considered as ATA positive. This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.

Time frame:
Up to 7 months
Reported as:
Number · percentage of participants
Phase 1: Percentage of Participants Who Were Antitherapeutic Antibody (ATA) Positive, Persistently Positive or Transiently Positive, and Neutralizing Antitherapeutic Antibody (nATA) Positive
percentage of participantsPhase 1: Brentuximab Vedotin 48 mg/m^2 +AVD
Transiently ATA Positive13
Persistently ATA Positive0
nATA Positive0
SecondaryPhase 2: Progression-free Survival (PFS)

PFS per IRF:time from first dose until disease progression per IRF/death due to any cause,whichever occurred first.Participants with no objective progressive disease (PD),did not die,were still on study follow-up at time of analysis were removed from study prior to documentation of PD,PFS was censored on date of last adequate disease assessment before initiation of any non-protocol,alternative therapy.Participants who were on antitumor treatment,other than SCT/radiotherapy,censoring was at last adequate disease assessment before initiation of such alternative treatment.If participant experienced disease progression per IRF/died after initiation of antitumor treatment,other than SCT/radiotherapy,such participant was censored and not considered having PFS.Outcome measure was planned to be assessed for all participant treated at recommended dose in Phase 2.As per SAP,Phase 2 data was summarized and reported in two arms:Phase 2 and Phase 1 + Phase 2.

Time frame:
Up to 24 months
Reported as:
Median · months
Phase 2: Progression-free Survival (PFS)
monthsPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Phase 2: Progression-free Survival (PFS)NA (NA to NA)NA (NA to NA)
SecondaryPhase 2: Event-free Survival (EFS)

EFS:Time from first dose until any treatment failure:PD per IRF including progression events during follow-up period,failing to complete 6 cycles of treatment due to any reason or death due to any cause,whichever occurred first.EFS per IRF were censored on last adequate disease assessment date per IRF if none of above events occur during study.Participants with antitumor treatment,other than SCT/radiotherapy as part of frontline treatment were censored at last adequate disease assessment before initiation of such alternative treatment.If a participant experienced disease progression per IRF/died after initiation of antitumor treatment,other than SCT/radiotherapy,such participant was censored,and not be considered having EFS.This outcome measure was planned to be assessed for all patients treated at recommended dose in Phase 2.As prespecified in SAP,data for Phase 2 was summarized and reported in two arms:Phase 2 and Phase 1 + Phase 2.

Time frame:
Up to 24 months
Reported as:
Median · months
Phase 2: Event-free Survival (EFS)
monthsPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Phase 2: Event-free Survival (EFS)NA (NA to NA)NA (NA to NA)
SecondaryPhase 2: Overall Survival (OS)

Overall survival was defined as time from first dose until death. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive, including study closure. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
Up to 24 months
Reported as:
Median · months
Phase 2: Overall Survival (OS)
monthsPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Phase 2: Overall Survival (OS)NA (NA to NA)NA (NA to NA)
SecondaryPhase 2: Duration of Response (DOR)

DOR per IRF in participants with a response (CR or PR per IRF) was defined as the time from start of the first objective tumor response (CR or PR per IRF) to the first subsequent PD or death due to any cause, whichever occurred first. For patients who did not have an objective PD, did not die and are either still on a study follow-up at the time of the analysis, or were removed from the study prior to documentation of PD, DOR has been censored on the date of last adequate disease assessment. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
Up to 24 months
Reported as:
Median · months
Phase 2: Duration of Response (DOR)
monthsPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Phase 2: Duration of Response (DOR)NA (NA to NA)NA (NA to NA)
SecondaryPhase 2: Percentage of Participants Receiving Irradiation for HL Following Study Treatment

This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
Up to 24 months
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants Receiving Irradiation for HL Following Study Treatment
percentage of participantsPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Phase 2: Percentage of Participants Receiving Irradiation for HL Following Study Treatment25 (14 to 40)24 (14 to 37)
SecondaryPhase 2: Percentage of Participants Who Experienced AEs From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy

This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
From first dose in Cycle 1 Day 1 until 30 days after the last dose of study drug in Cycle 6 Day 15 (up to Cycle 7 Day 15) (Cycle length=28 days)
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants Who Experienced AEs From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy
percentage of participantsPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Phase 2: Percentage of Participants Who Experienced AEs From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy100100
SecondaryPhase 2: Percentage of Participants Who Experienced SAEs From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy

This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
From first dose in Cycle 1 Day 1 until 30 days after the last dose of study drug in Cycle 6 Day 15 (up to Cycle 7 Day 15) (Cycle length=28 days)
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants Who Experienced SAEs From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy
percentage of participantsPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Phase 2: Percentage of Participants Who Experienced SAEs From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol Therapy4541
SecondaryPhase 2: Percentage of Participants Who Were ATA Positive, Persistently Positive, or Transiently Positive, and nATA Positive

ATA positive was defined as participants who have a positive ATA in any postbaseline sample. Transiently ATA positive was defined as participants who have positive ATA in 1 or 2 postbaseline samples. Persistently ATA positive was defined as participants who have positive ATA in more than 2 postbaseline timepoints. Transiently ATA positive was defined as participants who have positive ATA in 1 or 2 postbaseline samples. nATA positive was defined as participants who have at least one positive nATA in any postbaseline ATA positive sample. Here, percentage of participants who were transiently or persistently ATA positive are considered as ATA positive. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
From first dose until 30 days after the last dose of study drug (up to 7 months)
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants Who Were ATA Positive, Persistently Positive, or Transiently Positive, and nATA Positive
percentage of participantsPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Transiently ATA Positive67
Persistently ATA Positive00
nATA Positive43
SecondaryPhase 2: Mean Serum Cmax of Brentuximab Vedotin and TAb

This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Reported as:
Mean · µg/mL
Phase 2: Mean Serum Cmax of Brentuximab Vedotin and TAb
µg/mLPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Cmax of Brentuximab Vedotin at Cycle 1 Day 123.1 ± 5.5423.0 ± 5.21
Cmax of Brentuximab Vedotin at Cycle 1 Day 1525.3 ± 5.1224.9 ± 4.97
Cmax of Brentuximab Vedotin at Cycle 3 Day 127.4 ± 6.1427.3 ± 5.82
Cmax of Brentuximab Vedotin at Cycle 3 Day 1525.4 ± 4.0325.8 ± 4.81
Cmax of TAb Vedotin at Cycle 1 Day 122.1 ± 5.3422.4 ± 5.23
Cmax of TAb Vedotin at Cycle 1 Day 1526.5 ± 9.0226.4 ± 8.52
Cmax of TAb Vedotin at Cycle 3 Day 129.5 ± 8.8929.5 ± 8.44
Cmax of TAb Vedotin at Cycle 3 Day 1532.2 ± 11.031.4 ± 10.4
SecondaryPhase 2: Mean Plasma Cmax of MMAE

This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Reported as:
Mean · ng/mL
Phase 2: Mean Plasma Cmax of MMAE
ng/mLPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Cycle 1 Day 15.49 ± 2.625.49 ± 2.80
Cycle 1 Day 152.95 ± 1.662.81 ± 1.57
Cycle 3 Day 11.75 ± 0.6431.69 ± 0.635
Cycle 3 Day 151.74 ± 0.5991.61 ± 0.597
SecondaryPhase 2: Mean Serum AUC0-15d of Brentuximab Vedotin and TAb

This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Reported as:
Mean · day*µg/mL
Phase 2: Mean Serum AUC0-15d of Brentuximab Vedotin and TAb
day*µg/mLPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
AUC0-15d of Brentuximab Vedotin at Cycle 1 Day 149.7 ± 17.248.8 ± 16.3
AUC0-15d of Brentuximab Vedotin at Cycle 1 Day 1554.9 ± 22.254.0 ± 20.6
AUC0-15d of Brentuximab Vedotin at Cycle 3 Day 162.6 ± 16.963.9 ± 18.6
AUC0-15d of Brentuximab Vedotin at Cycle 3 Day 1560.6 ± 11.161.4 ± 11.5
AUC0-15d of TAb at Cycle 1 Day 177.2 ± 18.677.6 ± 18.0
AUC0-15d of TAb at Cycle 1 Day 1597.3 ± 28.798.1 ± 27.0
AUC0-15d of TAb at Cycle 3 Day 1119 ± 30.6120 ± 29.1
AUC0-15d of TAb at Cycle 3 Day 15124 ± 21.6125 ± 24.1
SecondaryPhase 2: Mean Plasma AUC0-15 of MMAE

This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Reported as:
Mean · day*ng/mL
Phase 2: Mean Plasma AUC0-15 of MMAE
day*ng/mLPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Cycle 1 Day 131.2 ± 16.231.0 ± 16.8
Cycle 1 Day 1518.4 ± 11.917.9 ± 11.4
Cycle 3 Day 111.5 ± 5.1611.1 ± 4.93
Cycle 3 Day 1512.3 ± 6.1211.3 ± 5.90
SecondaryPhase 2: Median Tmax of Brentuximab Vedotin and TAb in Serum

This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Reported as:
Median · hour
Phase 2: Median Tmax of Brentuximab Vedotin and TAb in Serum
hourPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Tmax of Brentuximab Vedotin at Cycle 1 Day 11.03 (0.530 to 164)1.00 (0.530 to 164)
Tmax of Brentuximab Vedotin at Cycle 1 Day 151.00 (0.500 to 22.7)1.00 (0.500 to 22.7)
Tmax of Brentuximab Vedotin at Cycle 3 Day 11.00 (0.00 to 23.0)1.00 (0.00 to 23.0)
Tmax of Brentuximab Vedotin at Cycle 3 Day 151.00 (0.520 to 1.50)1.00 (0.520 to 1.50)
Tmax of TAb at Cycle 1 Day 11.01 (0.530 to 20.8)1.00 (0.530 to 20.8)
Tmax of TAb at Cycle 1 Day 151.00 (0.500 to 334)1.00 (0.500 to 334)
Tmax of TAb at Cycle 3 Day 11.00 (0.00 to 23.3)1.00 (0.00 to 23.3)
Tmax of TAb at Cycle 3 Day 151.00 (0.520 to 1.50)1.00 (0.520 to 1.50)
SecondaryPhase 2: Median Tmax of MMAE in Plasma

This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
Days 1 and 15 of Cycles 1 and 3 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Reported as:
Median · hour
Phase 2: Median Tmax of MMAE in Plasma
hourPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Cycle 1 Day 144.1 (19.7 to 72.0)44.4 (19.7 to 72.0)
Cycle 1 Day 1542.9 (20.0 to 72.0)42.9 (20.0 to 72.0)
Cycle 3 Day 144.9 (20.3 to 71.7)45.3 (20.3 to 71.7)
Cycle 3 Day 1545.4 (20.0 to 71.7)46.0 (20.0 to 71.7)
SecondaryPhase 2: Percentage of Participants Who Experienced Peripheral Neuropathy, Regardless of Seriousness, From the First Dose of Protocol Therapy

Peripheral Neuropathy (PN) was defined by the peripheral neuropathy standardized MedDRA query (SMQ) broad search. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
Up to 24 months
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants Who Experienced Peripheral Neuropathy, Regardless of Seriousness, From the First Dose of Protocol Therapy
percentage of participantsPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Phase 2: Percentage of Participants Who Experienced Peripheral Neuropathy, Regardless of Seriousness, From the First Dose of Protocol Therapy2019
SecondaryPhase 2: Time to Onset and Resolution for All Peripheral Neuropathy Events

Time to onset of first event was defined as time from first dose of study drug to onset of first treatment-emergent PN event. Time to resolution was calculated as the time from onset date to the date of resolution PN (SMQ) event. Participants with multiple resolved events were counted once at the longest time to resolution. Resolution was defined as an event outcome of resolved or resolved with sequelae. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
Up to 24 months
Reported as:
Median · weeks
Phase 2: Time to Onset and Resolution for All Peripheral Neuropathy Events
weeksPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Time to Onset5.93 (0.9 to 19.9)5.93 (0.9 to 19.9)
Time to Resolution1.57 (0.3 to 100.3)1.57 (0.3 to 100.3)
SecondaryPhase 2: Immune Reconstitution-Change From Baseline Immunoglobulin G Levels at End of Treatment (EOT)

This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
Baseline and End of Treatment (Month 7)
Reported as:
Mean · g/L
Phase 2: Immune Reconstitution-Change From Baseline Immunoglobulin G Levels at End of Treatment (EOT)
g/LPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Baseline16.518 ± 5.530616.217 ± 5.2175
Change from Baseline at EOT-4.822 ± 4.8964-4.675 ± 4.7204
SecondaryPhase 1: Percentage of Participants With Low and High ATA Titer Values

High ATA titer was defined as participants who have at least one postbaseline ATA titer less than (\>) 25. Low ATA titer was defined as participants whose postbaseline ATA titer are all less than or equal to (\<=) 25. This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.

Time frame:
Up to 6 months
Reported as:
Number · percentage of participants
Phase 1: Percentage of Participants With Low and High ATA Titer Values
percentage of participantsPhase 1: Brentuximab Vedotin 48 mg/m^2 + AVD
ATA Titer low13
ATA Titer High0
SecondaryPhase 2: Percentage of Participants With Low and High ATA Titer Values

High ATA titer was defined as participants who have at least one postbaseline ATA titer \>25. Low ATA titer was defined as participants whose postbaseline ATA titer are all \<=25. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
Up to 6 months
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants With Low and High ATA Titer Values
percentage of participantsPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
ATA Titer Low67
ATA Titer High00
SecondaryPhase 1: Mean Cmax of Brentuximab Vedotin in ATA Positive and ATA Negative Participants

This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.

Time frame:
Cycle 1 and 3: Days 1 and 15 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Reported as:
Mean · µg/mL
Phase 1: Mean Cmax of Brentuximab Vedotin in ATA Positive and ATA Negative Participants
µg/mLPhase 1: Brentuximab Vedotin 48 mg/m^2 + AVD
ATA Positive: Cycle 1 Day 123.3 ± NA
ATA Positive: Cycle 1 Day 1521.1 ± NA
ATA Positive: Cycle 3 Day 123.1 ± NA
ATA Positive: Cycle 3 Day 1521.6 ± NA
ATA Negative: Cycle 1 Day 122.5 ± 1.62
ATA Negative: Cycle 1 Day 1523.5 ± 4.17
ATA Negative: Cycle 3 Day 127.2 ± 3.62
ATA Negative: Cycle 3 Day 1528.3 ± 7.32
SecondaryPhase 1: Mean AUC 0-15d of Brentuximab Vedotin in ATA Positive and ATA Negative Participants

This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.

Time frame:
Cycle 1 and 3: Days 1 and 15 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Reported as:
Mean · day*µg/mL
Phase 1: Mean AUC 0-15d of Brentuximab Vedotin in ATA Positive and ATA Negative Participants
day*µg/mLPhase 1: Brentuximab Vedotin 48 mg/m^2 + AVD
ATA Positive: Cycle 1 Day 142.4 ± NA
ATA Positive: Cycle 1 Day 1550.0 ± NA
ATA Positive: Cycle 3 Day 156.6 ± NA
ATA Positive: Cycle 3 Day 1563.0 ± NA
ATA Negative: Cycle 1 Day 142.2 ± 3.40
ATA Negative: Cycle 1 Day 1548.6 ± 6.48
ATA Negative: Cycle 3 Day 175.4 ± 29.46
ATA Negative: Cycle 3 Day 1565.1 ± 15.06
SecondaryPhase 1: Percentage of Participants Achieving CR Per IRF Assessment Per IWG Criteria in ATA Positive and ATA Negative Participants

CR was defined as the disappearance of all evidence of disease as assessed by IRF as per IWG Criteria. The data is reported per ATA status as categories. This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.

Time frame:
Up to 24 months
Reported as:
Number · percentage of participants
Phase 1: Percentage of Participants Achieving CR Per IRF Assessment Per IWG Criteria in ATA Positive and ATA Negative Participants
percentage of participantsPhase 1: Brentuximab Vedotin 48 mg/m^2 + AVD
ATA Negative who Achieved CR86 (42 to 100)
Transiently ATA Positive who Achieved CR100 (3 to 100)
SecondaryPhase 1: Number of ATA Positive and ATA Negative Participants With AEs and SAEs

This outcome measure is planned to be assessed only for participants treated in Phase 1 arm.

Time frame:
Up to 24 months
Reported as:
Count of participants · Participants
Phase 1: Number of ATA Positive and ATA Negative Participants With AEs and SAEs
ParticipantsPhase 1: Brentuximab Vedotin 48 mg/m^2 + AVD
ATA Negative: AEs7
ATA Positive: AEs1
ATA Negative: SAEs0
ATA Positive: SAEs1
SecondaryPhase 2: Mean Cmax of Brentuximab Vedotin in ATA Positive and ATA Negative Participants

This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
Cycle 1-3: Days 1 and 15 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Reported as:
Mean · µg/mL
Phase 2: Mean Cmax of Brentuximab Vedotin in ATA Positive and ATA Negative Participants
µg/mLPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
ATA Positive: Cycle 1 Day 127.8 ± 8.5626.7 ± 7.34
ATA Positive: Cycle 1 Day 1523.3 ± 6.8822.7 ± 5.72
ATA Positive: Cycle 3 Day 122.0 ± 2.9222.4 ± 2.15
ATA Positive: Cycle 3 Day 1525.6 ± 7.9324.2 ± 6.07
ATA Negative: Cycle 1 Day 122.8 ± 5.2922.7 ± 5.00
ATA Negative: Cycle 1 Day 1525.4 ± 5.0225.2 ± 4.91
ATA Negative: Cycle 3 Day 127.7 ± 6.1427.6 ± 5.84
ATA Negative: Cycle 3 Day 1525.4 ± 3.8526.0 ± 4.76
SecondaryPhase 2: Mean AUC 0-15 of Brentuximab Vedotin in ATA Positive and ATA Negative Participants

This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
Cycle 1-3: Days 1 and 15 pre-infusion and up to 30 minutes after the end of infusion (Cycle length=28 days)
Reported as:
Mean · day*µg/mL
Phase 2: Mean AUC 0-15 of Brentuximab Vedotin in ATA Positive and ATA Negative Participants
day*µg/mLPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
ATA Positive: Cycle 1 Day 151.6 ± 17.1749.3 ± 14.75
ATA Positive: Cycle 1 Day 1545.6 ± 38.8746.7 ± 31.81
ATA Positive: Cycle 3 Day 153.7 ± 10.1654.6 ± 7.38
ATA Positive: Cycle 3 Day 1557.2 ± 12.3759.1 ± 9.38
ATA Negative: Cycle 1 Day 149.6 ± 17.4148.8 ± 16.58
ATA Negative: Cycle 1 Day 1555.8 ± 20.7754.8 ± 19.52
ATA Negative: Cycle 3 Day 163.0 ± 17.1064.4 ± 18.99
ATA Negative: Cycle 3 Day 1560.9 ± 11.2361.7 ± 11.81
SecondaryPhase 2: Percentage of Participants Achieving CR Per IRF Assessment Per IWG Criteria in ATA Positive and ATA Negative Participants

CR is defined as the disappearance of all evidence of disease as assessed by IRF as per IWG Criteria. This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
Up to 24 months
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants Achieving CR Per IRF Assessment Per IWG Criteria in ATA Positive and ATA Negative Participants
percentage of participantsPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
ATA Negative75 (60 to 86)76 (63 to 87)
Transiently ATA Positive67 (9 to 99)75 (19 to 99)
SecondaryPhase 2: Number of ATA Positive and ATA Negative Participants With AEs and SAEs

This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
Up to 24 months
Reported as:
Count of participants · Participants
Phase 2: Number of ATA Positive and ATA Negative Participants With AEs and SAEs
ParticipantsPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
ATA Negative: AEs4855
ATA Positive: AEs34
ATA Negative: SAEs2121
ATA Positive: SAEs23
SecondaryPhase 2: Immune Reconstitution-Change From Baseline in Immunoglobulin M at the End of Treatment (EOT)

This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
Baseline, EOT [Month 7]
Reported as:
Mean · g/L
Phase 2: Immune Reconstitution-Change From Baseline in Immunoglobulin M at the End of Treatment (EOT)
g/LPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Baseline1.275 ± 0.50651.261 ± 0.4824
Change at EOT (Month 7)-0.345 ± 0.5942-0.375 ± 0.5766
SecondaryPhase 2: Immune Reconstitution-Change From Baseline in Immunoglobulin A at EOT

This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
Baseline, EOT [Month 7]
Reported as:
Mean · g/L
Phase 2: Immune Reconstitution-Change From Baseline in Immunoglobulin A at EOT
g/LPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Baseline2.708 ± 1.23792.671 ± 1.1879
Change from Baseline at EOT-0.195 ± 1.0479-0.125 ± 1.0844
SecondaryPhase 2: Immune Reconstitution-Change From Baseline in Tetanus at EOT

This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
Baseline, EOT [Month 7]
Reported as:
Mean · (IU)/mL
Phase 2: Immune Reconstitution-Change From Baseline in Tetanus at EOT
(IU)/mLPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Baseline1.636 ± 2.56001.935 ± 3.0358
Change from Baseline at EOT-0.648 ± 1.3412-0.914 ± 2.2679
SecondaryPhase 2: Immune Reconstitution-Change From Baseline in Haemophilus Influenzae B Antibody, IgG at EOT

This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
Baseline, EOT [Month 7]
Reported as:
Mean · µg/mL
Phase 2: Immune Reconstitution-Change From Baseline in Haemophilus Influenzae B Antibody, IgG at EOT
µg/mLPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Baseline10.39 ± 27.0179.50 ± 25.167
Change from Baseline at EOT-7.00 ± 24.258-6.03 ± 23.160
SecondaryPhase 2: Immune Reconstitution-Change From Baseline Poliovirus Antibodies Ratio at EOT

This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
Baseline, EOT [Month 7]
Reported as:
Mean · ratio
Phase 2: Immune Reconstitution-Change From Baseline Poliovirus Antibodies Ratio at EOT
ratioPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Baseline: Type I0.02447 ± 0.0275680.02373 ± 0.028092
EOT: Type I0.00913 ± 0.0242230.00845 ± 0.023091
Baseline: Type III0.03641 ± 0.0367090.03432 ± 0.036653
EOT: Type III0.01141 ± 0.0298890.01013 ± 0.028461
SecondaryPhase 2: Immune Reconstitution-Change From Baseline Total Immunoglobulin at EOT

This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
Baseline, EOT [Month 7]
Reported as:
Mean · mg/dl
Phase 2: Immune Reconstitution-Change From Baseline Total Immunoglobulin at EOT
mg/dlPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Baseline2086.6 ± 615.622045.1 ± 583.04
Change from Baseline at EOT-582.3 ± 565.52-556.3 ± 553.97
SecondaryPhase 2: Immune Reconstitution-Change From Baseline in Peripheral Blood CD34+A at EOT

This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
Baseline, EOT [Month 7]
Reported as:
Mean · µL
Phase 2: Immune Reconstitution-Change From Baseline in Peripheral Blood CD34+A at EOT
µLPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Baseline4.182 ± 4.12273.917 ± 3.8917
Change from Baseline at EOT-1.512 ± 4.7075-1.456 ± 4.3472
SecondaryPhase 2: Immune Reconstitution-Change From Baseline in Total Lymphocyte Count at EOT

This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
Baseline, EOT [Month 7]
Reported as:
Mean · 10^9 lymphocytes/L
Phase 2: Immune Reconstitution-Change From Baseline in Total Lymphocyte Count at EOT
10^9 lymphocytes/LPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Baseline1.8022 ± 0.952061.7408 ± 0.91394
Change from Baseline at EOT0.6736 ± 3.776110.5965 ± 3.50121
SecondaryPhase 2: Immune Reconstitution-Change From Baseline in the Percentage of CD4+ (CD4+CD45RA-CD197- and CD4+CD45RA+CD197+) Subset of Cells at EOT

This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
Baseline, EOT [Month 7]
Reported as:
Mean · percentage of CD4+ subset cells
Phase 2: Immune Reconstitution-Change From Baseline in the Percentage of CD4+ (CD4+CD45RA-CD197- and CD4+CD45RA+CD197+) Subset of Cells at EOT
percentage of CD4+ subset cellsPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Baseline: CD4+CD45RA-CD197-28.0 ± 12.7629.0 ± 13.42
Change from Baseline at EOT: CD4+CD45RA-CD197--5.0 ± 17.72-5.1 ± 16.44
Baseline: CD4+CD45RA-CD197+23.7 ± 14.3322.3 ± 13.86
Change from Baseline at EOT: CD4+CD45RA-CD197+13.0 ± 14.1412.6 ± 13.21
Baseline: CD4+CD45RA+CD197-2.9 ± 3.413.1 ± 3.22
Change from Baseline at EOT: CD4+CD45RA+CD197--0.7 ± 2.25-0.7 ± 2.41
Baseline: CD4+CD45RA+CD197+46.2 ± 14.4446.3 ± 14.89
Change from Baseline at EOT: CD4+CD45RA+CD197+-7.2 ± 11.60-6.8 ± 11.04
SecondaryPhase 2: Immune Reconstitution-Change From Baseline in the Percentage of CD8+ (CD8+CD45RA-CD197- and CD8+CD45RA-CD197+) Subset of Cells at EOT

This outcome measure was planned to be assessed only for all participants treated at the recommended dose in Phase 2. As prespecified in SAP, data for Phase 2 was summarized and reported in two arms: Phase 2 and Phase 1 + Phase 2.

Time frame:
Baseline, EOT [Month 7]
Reported as:
Mean · percentage of CD8+ subset cells
Phase 2: Immune Reconstitution-Change From Baseline in the Percentage of CD8+ (CD8+CD45RA-CD197- and CD8+CD45RA-CD197+) Subset of Cells at EOT
percentage of CD8+ subset cellsPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 1 + Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Baseline: CD8+CD45RA-CD197-39.9 ± 19.3240.6 ± 20.00
Change from Baseline at EOT: CD8+CD45RA-CD197--11.5 ± 13.85-11.0 ± 14.33
Baseline: CD8+CD45RA-CD197+2.4 ± 1.812.3 ± 1.76
Change from Baseline at EOT: CD8+CD45RA-CD197+1.6 ± 2.522.1 ± 3.08
Baseline: CD8+CD45RA+CD197-25.9 ± 15.4325.8 ± 14.60
Change from Baseline at EOT: CD8+CD45RA+CD197--6.0 ± 11.27-6.5 ± 11.83
Baseline: CD8+CD45RA+CD197+31.3 ± 18.0030.8 ± 18.53
Change from Baseline at EOT: CD8+CD45RA+CD197+15.7 ± 11.4815.4 ± 12.15

Adverse events

Collected over From first dose of study drug up to data cut -off date: 24 September 2021 (Up to approximately 4 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1: Brentuximab Vedotin 48 mg/m^2 + AVD0/8 (0%)1/8 (12.5%)8/8 (100%)
Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD0/51 (0%)23/51 (45.1%)51/51 (100%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventPhase 1: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
Febrile neutropeniaBlood and lymphatic system disorders1/89/51
NeutropeniaBlood and lymphatic system disorders0/83/51
VomitingGastrointestinal disorders0/83/51
ConstipationGastrointestinal disorders0/82/51
Gastrointestinal disorderGastrointestinal disorders0/82/51
NauseaGastrointestinal disorders0/82/51
SepsisInfections and infestations0/82/51
PyrexiaGeneral disorders0/82/51
AnaemiaBlood and lymphatic system disorders0/81/51
Abdominal painGastrointestinal disorders0/81/51
Most frequent other events
Showing 10 of 86
Most frequent other events
EventPhase 1: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVD
VomitingGastrointestinal disorders8/842/51
NauseaGastrointestinal disorders8/836/51
Abdominal pain upperGastrointestinal disorders8/87/51
NeutropeniaBlood and lymphatic system disorders8/820/51
AstheniaGeneral disorders5/83/51
White blood cell count decreasedInvestigations5/820/51
HeadacheNervous system disorders5/814/51
StomatitisGastrointestinal disorders4/821/51
ConstipationGastrointestinal disorders4/817/51
DiarrhoeaGastrointestinal disorders4/810/51

Baseline characteristics

The safety population included participants who had received at least 1 dose of any study drug (A+AVD regimen).

Age, Continuous
Age, Continuous(years)Phase 1: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDTotal
Mean12.4 ± 3.8113.9 ± 2.8813.7 ± 3.03
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDTotal
Female42428
Male42731
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDTotal
Hispanic or Latino22123
Not Hispanic or Latino62632
Unknown or Not Reported044
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Phase 1: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDTotal
Asian033
Black or African American01212
White82634
"Brown" or "Mulatto"099
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(Participants)Phase 1: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDTotal
United States21012
Japan022
Italy51015
Brazil12930
Weight
Weight(kilograms (kg))Phase 1: Brentuximab Vedotin 48 mg/m^2 + AVDPhase 2: Brentuximab Vedotin 48 mg/m^2 + AVDTotal
Mean45.91 ± 18.86749.91 ± 15.64949.37 ± 16.000
08

Study locations

14 sites
09

References and documents

Publications

  • Suri A, Mould DR, Song G, Kinley J, Venkatakrishnan K. Population Pharmacokinetics of Brentuximab Vedotin in Adult and Pediatric Patients With Relapsed/Refractory Hematologic Malignancies: Model-Informed Hypothesis Generation for Pediatric Dosing Regimens. J Clin Pharmacol. 2020 Dec;60(12):1585-1597. doi: 10.1002/jcph.1682. Epub 2020 Jun 28. PubMed 32596842 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in May 2020, 31 months.

Results were first posted in Jun 2021, 1 year after primary completion.

Of 63 phase 1/2 interventional studies under Hodgkin Disease, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 53 and three quarters within 97. This study's 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2016
First posted
Dec 1, 2016
StartActual
Sep 6, 2017
Primary completionActual
May 5, 2020
CompletionEst.
Sep 24, 2029
Results first posted
Jun 1, 2021
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date and references
1 update, last Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Minor edits only
    + 3 other changes: identifiers, verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02979522
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Dec 1, 2016
Start date
Sep 6, 2017
Primary completion
May 5, 2020
Completion
Sep 24, 2029 (estimated)
Results posted
Jun 1, 2021
Last update
Nov 10, 2026

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Brentuximab Vedotin · Doxorubicin · Vinblastine · Dacarbazine

Start the discussion